WS #16686
Novartis announced that its Phase III ORION-4 clinical trial for pelacarsen missed its primary endpoint. This failure represents a setback for the antisense oligonucleotide approach to lipid management and may dampen sentiment for competitors in the non-statin cholesterol space. The news is isolated to the biotech sector and does not appear to have broader macro implications.
Biotech Clinical Setbacks
Novartis announced that its Phase III ORION-4 clinical trial for pelacarsen missed its primary endpoint. This failure represents a setback for the antisense oligonucleotide approach to lipid management and may dampen sentiment for competitors in the non-statin cholesterol space. The news is isolated to the biotech sector and does not appear to have broader macro implications.